MRES (Institute of Biomedical Research) Beta: 1.7829 (As of Jun. 26, 2026)


What is Institute of Biomedical Research Beta?

Institute of Biomedical Research MRES Beta is 1.7829 as of Jun. 26, 2026.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Institute of Biomedical Research's Beta is 1.7829.


Institute of Biomedical Research  (OTCPK:MRES) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Institute of Biomedical Research Beta Related Terms


Institute of Biomedical Research Beta Historical Data

* Premium members only.

The historical data trend for Institute of Biomedical Research's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Institute of Biomedical Research Beta Chart

Institute of Biomedical Research Annual Data
Trend Dec03 Dec04 Mar06 Mar07 Mar08 Mar09 Mar10
Beta
Get a 7-Day Free Trial -11.48 -22.40 -7.62 1.10 5.92

Institute of Biomedical Research Quarterly Data
Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.35 5.92 6.67 5.48 5.08

MRES vs HSTC, NTRR, VITIF: Beta Comparison

For the Biotechnology subindustry, Institute of Biomedical Research's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Institute of Biomedical Research Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Institute of Biomedical Research's Beta distribution charts can be found below:

* The bar in red indicates where Institute of Biomedical Research's Beta falls into.



Institute of Biomedical Research Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.7829 mean?
Institute of Biomedical Research (MRES) has a Beta of 1.7829 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Institute of Biomedical Research and its competitors.
Is Institute of Biomedical Research's Beta too high?
Institute of Biomedical Research's current Beta is 1.7829.
How does Institute of Biomedical Research's Beta compare to HSTC and NTRR?
Institute of Biomedical Research's Beta of 1.7829 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Institute of Biomedical Research and its competitors. Institute of Biomedical Research's current Beta is 1.7829. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Institute of Biomedical Research stock overvalued right now?
Institute of Biomedical Research (MRES) has a current Beta of 1.7829. The current Beta is 1.7829. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Institute of Biomedical Research (MRES), the current Beta is 1.7829 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Institute of Biomedical Research Business Description

Address Dubai Science Park, 13th Floor, South Tower, Dubai, ARE, 416452
Institute of Biomedical Research Corp is a biomedical research and development company. The company is focused on alternative plant-based food and medicine and mental health therapeutic research. The company uses brand name M2Bio Sciences engaged in deploying artificial intelligence, science and medicine, clinical research, and emerging technologies.